Biolargo Revenue Plunges 56% to $7.8M in 2025, Net Loss Widens on Credit Loss
Summary
Biolargo Inc. reported a significant deterioration in its 2025 financial results, with revenue plummeting 56% year-over-year to $7.765 million. The company posted a net loss of $15.189 million, a substantial increase from the prior year's $4.347 million loss, leading to an EPS of $(0.04). This sharp decline was primarily attributed to a $3.886 million credit loss related to a major private-label partner and a collapse in product sales volumes. The substantial revenue contraction and widened losses highlight severe operational challenges and financial headwinds for the company. Traders should note the material impact of the credit loss and the company's expectation of continued revenue pressure in 2026 without securing a new private-label partner. Future catalysts will depend on the successful commercialization of new initiatives like ViaCLYR and advancements in Clyra and BETI.
At the time of this announcement, BLGO was trading at $0.18 on OTC in the Life Sciences sector, with a market capitalization of approximately $56.3M. The 52-week trading range was $0.14 to $0.30. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.